Global PARP (Poly ADP-Ribose Polymerase) Inhibitor Market: Industry Analysis & Outlook (2018-2025)
PARP means poly (adenosine diphosphate [ADP] -ribose) polymerase. It is a family of 17 enzymes that combine several (poly) units of ADP-ribose in a chain (the PAR chain) and transfers them to the target proteins. This helps to restore DNA when it is damaged. DNA can be damaged by many factors, including exposure to UV rays, radiation, some anti-cancer drugs or other substances in the environment. PARP inhibitors block an enzyme critical to the repair of single stranded breaks in DNA. Inhibition of this DNA repair enzyme can lead to cell death, particularly in cancer cells that carry deficiency in other DNA repair pathways.
PARP inhibitors play an effective maintenance role in current cancer-combating strategies with its superior effect to that of existing ovarian cancer treatment. Currently, Talazoparib and Veliparib are in Phase III clinical trials and Rucaparib, Olaparib and Niraparib are approved PARP drugs which are currently present in the market for ovarian cancer. PARP inhibitors improve progression-free survival in women with recurrent ovarian cancer, sensitive to platinum.
The U.S. is the major market of PARP inhibitor supported by PARPi for ovarian cancer in the market. The U.S. region is likely to experience further growth of PARP inhibitor market with upcoming PARP inhibitors and growing cases of cancer.
The global PARP inhibitor market is expected to grow in future due to increasing ageing population, rising cancer incidences, rise in health expenditure and improving economic conditions and vast unmet medical need. Key trends in this market include a combination of PARP and immuno therapy, increasing awareness, development of biomarkers and strong research and development efforts. However, there are some factors which can hinder the market growth including side effects, resistance to PARP inhibitors and regulatory challenges.
The report “Global PARP Inhibitor Market: Industry Analysis & Outlook (2018-2025)” by Koncept Analytics provides an extensive research and detailed analysis of the present market along with future outlook. The report discusses the major growth drivers and challenges of the market, covering the U.S. and Europe region along with the global market. The four major players: Tesaro Inc., Clovis Oncology, AstraZeneca and Abbvie Inc. are being profiled along with their key financials and strategies for growth.
PARP inhibitors play an effective maintenance role in current cancer-combating strategies with its superior effect to that of existing ovarian cancer treatment. Currently, Talazoparib and Veliparib are in Phase III clinical trials and Rucaparib, Olaparib and Niraparib are approved PARP drugs which are currently present in the market for ovarian cancer. PARP inhibitors improve progression-free survival in women with recurrent ovarian cancer, sensitive to platinum.
The U.S. is the major market of PARP inhibitor supported by PARPi for ovarian cancer in the market. The U.S. region is likely to experience further growth of PARP inhibitor market with upcoming PARP inhibitors and growing cases of cancer.
The global PARP inhibitor market is expected to grow in future due to increasing ageing population, rising cancer incidences, rise in health expenditure and improving economic conditions and vast unmet medical need. Key trends in this market include a combination of PARP and immuno therapy, increasing awareness, development of biomarkers and strong research and development efforts. However, there are some factors which can hinder the market growth including side effects, resistance to PARP inhibitors and regulatory challenges.
The report “Global PARP Inhibitor Market: Industry Analysis & Outlook (2018-2025)” by Koncept Analytics provides an extensive research and detailed analysis of the present market along with future outlook. The report discusses the major growth drivers and challenges of the market, covering the U.S. and Europe region along with the global market. The four major players: Tesaro Inc., Clovis Oncology, AstraZeneca and Abbvie Inc. are being profiled along with their key financials and strategies for growth.
1. MARKET OVERVIEW
1.1 DNA Damage Response (DDR)
1.2 DNA Repair Pathways
1.3 PARP Inhibitor
1.4 Inhibiting PARP Mechanism
1.5 PARP for Cancer Treatment
1.6 PARP Inhibitor Drugs
2. GLOBAL MARKET ANALYSIS
2.1 Global PARP Inhibitor Market
2.1.1 Global PARP Inhibitor Market Forecast by Value
2.1.2 Global PARP Inhibitor Market Forecast by Cancer Type
2.1.3 Global PARP Inhibitor Market Share Forecast by Cancer Type
2.2 Global PARP Inhibitor Market by Drug Type
2.2.1 Global Lynparza Market Forecast by Value
2.2.2 Global Lynparza Market Forecast by Cancer Type
2.2.3 Global Lynparza Market Forecast by Region
2.2.4 Global Rubraca Market Forecast by Value
2.2.5 Global Rubraca Market Forecast by Cancer Type
2.2.6 Global Rubraca Ovarian Market Forecast by Line Therapy
2.2.7 Global Zejula Market Forecast by Value
2.2.8 Global Zejula Market Forecast by Cancer Type
2.2.9 Global Zejula Ovarian Market Forecast by Line Therapy
3. REGIONAL MARKET
3.1 The U.S.
3.1.1 The U.S. Ovarian Cancer Incidence Forecast
3.1.2 The U.S. Ovarian PARP Market Forecast by Value
3.1.3 The U.S. Ovarian Patients PARP Inhibitors Forecast by Drug
3.1.4 The U.S. Ovarian Cancer Patients Receiving PARP by Line Therapy
3.1.5 The U.S. Rubraca Market Forecast
3.1.6 The U.S. Zejula Market Forecast
3.2 European Union
3.2.1 EU Ovarian Cancer Incidence Forecast
3.2.2 EU Rubraca Market Forecast
3.2.3 EU/ROW Zejula Market Forecast
4. MARKET DYNAMICS
4.1 Growth Drivers
4.1.1 Rising Cancer Cases
4.1.2 Rising Healthcare Expenditure
4.1.3 Increased Ageing Population
4.1.4 Increasing GDP Per Capita
4.1.5 Vast Unmet Medical Need
4.2 Key Trends & Developments
4.2.1 Combinations of PARP Inhibitors and Immunotherapy
4.2.2 Development of Ovarian Cancer Diagnosis Methods and Biomarkers
4.2.3 Strong Research & Development Efforts by Companies
4.2.4 Increasing Awareness of Early Diagnosis and Treatment of Disease
4.3 Challenges
4.3.1 Side Effects of PARP Inhibitors
4.3.2 Resistance to PARP Inhibitors
4.3.3 Regulatory Challenges
5. COMPETITIVE LANDSCAPE
5.1 Global Market
5.1.1 Revenue and Market Cap Comparison
5.1.2 PARP Inhibitor Development by Company
6. COMPANY PROFILES
6.1 Tesaro Inc.
6.1.1 Business Overview
6.1.2 Financial Overview
6.1.3 Business Strategies
6.2 Clovis Oncology
6.2.1 Business Overview
6.2.2 Financial Overview
6.2.3 Business Strategies
6.3 AstraZeneca
6.3.1 Business Overview
6.3.2 Financial Overview
6.3.3 Business Strategies
6.4 Abbvie Inc.
6.4.1 Business Overview
6.4.2 Financial Overview
6.4.3 Business Strategies
1.1 DNA Damage Response (DDR)
1.2 DNA Repair Pathways
1.3 PARP Inhibitor
1.4 Inhibiting PARP Mechanism
1.5 PARP for Cancer Treatment
1.6 PARP Inhibitor Drugs
2. GLOBAL MARKET ANALYSIS
2.1 Global PARP Inhibitor Market
2.1.1 Global PARP Inhibitor Market Forecast by Value
2.1.2 Global PARP Inhibitor Market Forecast by Cancer Type
2.1.3 Global PARP Inhibitor Market Share Forecast by Cancer Type
2.2 Global PARP Inhibitor Market by Drug Type
2.2.1 Global Lynparza Market Forecast by Value
2.2.2 Global Lynparza Market Forecast by Cancer Type
2.2.3 Global Lynparza Market Forecast by Region
2.2.4 Global Rubraca Market Forecast by Value
2.2.5 Global Rubraca Market Forecast by Cancer Type
2.2.6 Global Rubraca Ovarian Market Forecast by Line Therapy
2.2.7 Global Zejula Market Forecast by Value
2.2.8 Global Zejula Market Forecast by Cancer Type
2.2.9 Global Zejula Ovarian Market Forecast by Line Therapy
3. REGIONAL MARKET
3.1 The U.S.
3.1.1 The U.S. Ovarian Cancer Incidence Forecast
3.1.2 The U.S. Ovarian PARP Market Forecast by Value
3.1.3 The U.S. Ovarian Patients PARP Inhibitors Forecast by Drug
3.1.4 The U.S. Ovarian Cancer Patients Receiving PARP by Line Therapy
3.1.5 The U.S. Rubraca Market Forecast
3.1.6 The U.S. Zejula Market Forecast
3.2 European Union
3.2.1 EU Ovarian Cancer Incidence Forecast
3.2.2 EU Rubraca Market Forecast
3.2.3 EU/ROW Zejula Market Forecast
4. MARKET DYNAMICS
4.1 Growth Drivers
4.1.1 Rising Cancer Cases
4.1.2 Rising Healthcare Expenditure
4.1.3 Increased Ageing Population
4.1.4 Increasing GDP Per Capita
4.1.5 Vast Unmet Medical Need
4.2 Key Trends & Developments
4.2.1 Combinations of PARP Inhibitors and Immunotherapy
4.2.2 Development of Ovarian Cancer Diagnosis Methods and Biomarkers
4.2.3 Strong Research & Development Efforts by Companies
4.2.4 Increasing Awareness of Early Diagnosis and Treatment of Disease
4.3 Challenges
4.3.1 Side Effects of PARP Inhibitors
4.3.2 Resistance to PARP Inhibitors
4.3.3 Regulatory Challenges
5. COMPETITIVE LANDSCAPE
5.1 Global Market
5.1.1 Revenue and Market Cap Comparison
5.1.2 PARP Inhibitor Development by Company
6. COMPANY PROFILES
6.1 Tesaro Inc.
6.1.1 Business Overview
6.1.2 Financial Overview
6.1.3 Business Strategies
6.2 Clovis Oncology
6.2.1 Business Overview
6.2.2 Financial Overview
6.2.3 Business Strategies
6.3 AstraZeneca
6.3.1 Business Overview
6.3.2 Financial Overview
6.3.3 Business Strategies
6.4 Abbvie Inc.
6.4.1 Business Overview
6.4.2 Financial Overview
6.4.3 Business Strategies
LIST OF CHARTS
Role of PARP
PARP Inhibitor Mechanism
Global PARP Inhibitor Market Forecast by Value (2017-2025)
Global PARP Inhibitor Market Forecast by Cancer Type (2017-2025)
Global PARP Inhibitor Market Share Forecast by Cancer Type (2020/2025)
Global PARP Inhibitor Market by Drug Type (2017)
Global Lynparza Market Forecast by Value (2017-2025)
Global Lynparza Market Forecast by Cancer Type (2017-2025)
Global Lynparza Market Forecast by Region (2017)
Global Rubraca Market Forecast by Value (2017-2025)
Global Rubraca Market Forecast by Cancer Type (2017-2025)
Global Rubraca Ovarian Market Forecast by Line Therapy (2017-2025)
Global Zejula Market Forecast by Value (2017-2025)
Global Zejula Market Forecast by Cancer Type (2017-2025)
Global Zejula Ovarian Market Forecast by Line Therapy (2017-2025)
The U.S. Ovarian Cancer Incidence Forecast (2017-2025)
The U.S. Ovarian PARP Market Forecast by Value (2017-2025)
The U.S. Ovarian New Patients PARP Inhibitors Forecast by Drug (2017-2025)
The U.S. Ovarian Cancer New Patients Receiving PARP by Line Therapy (2017-2025)
The U.S. Rubraca Market Forecast (2017-2025)
The U.S. Zejula Market Forecast (2017-2025)
EU Ovarian Cancer Incidence Forecast (2017-2025)
EU Rubraca Market Forecast (2017-2025)
EU/ROW Zejula Market Forecast (2017-2025)
Global New Cancer Cases (2012-2020)
Global Healthcare Expenditure Per Capita (2013-2017)
Global Ageing Population (2013-2017)
Global GDP Per Capita (2013-2017)
Tesaro Inc. Revenue and Net Loss (2012-2016)
Tesaro Inc. R&D Expenditure (2012-2016)
Clovis Oncology Revenue and Net Loss (2012-2016)
Clovis Oncology R&D Expenditure (2014-2016)
AstraZeneca Revenue by Segments (2017)
Revenue and Net Profit (2013-2017)
Abbvie Inc. Revenue by Geographic (2017)
Abbvie Inc. Revenue and Net Earnings (2013-2017)
Abbvie Inc. R&D Expenditure (2014-2017)
Role of PARP
PARP Inhibitor Mechanism
Global PARP Inhibitor Market Forecast by Value (2017-2025)
Global PARP Inhibitor Market Forecast by Cancer Type (2017-2025)
Global PARP Inhibitor Market Share Forecast by Cancer Type (2020/2025)
Global PARP Inhibitor Market by Drug Type (2017)
Global Lynparza Market Forecast by Value (2017-2025)
Global Lynparza Market Forecast by Cancer Type (2017-2025)
Global Lynparza Market Forecast by Region (2017)
Global Rubraca Market Forecast by Value (2017-2025)
Global Rubraca Market Forecast by Cancer Type (2017-2025)
Global Rubraca Ovarian Market Forecast by Line Therapy (2017-2025)
Global Zejula Market Forecast by Value (2017-2025)
Global Zejula Market Forecast by Cancer Type (2017-2025)
Global Zejula Ovarian Market Forecast by Line Therapy (2017-2025)
The U.S. Ovarian Cancer Incidence Forecast (2017-2025)
The U.S. Ovarian PARP Market Forecast by Value (2017-2025)
The U.S. Ovarian New Patients PARP Inhibitors Forecast by Drug (2017-2025)
The U.S. Ovarian Cancer New Patients Receiving PARP by Line Therapy (2017-2025)
The U.S. Rubraca Market Forecast (2017-2025)
The U.S. Zejula Market Forecast (2017-2025)
EU Ovarian Cancer Incidence Forecast (2017-2025)
EU Rubraca Market Forecast (2017-2025)
EU/ROW Zejula Market Forecast (2017-2025)
Global New Cancer Cases (2012-2020)
Global Healthcare Expenditure Per Capita (2013-2017)
Global Ageing Population (2013-2017)
Global GDP Per Capita (2013-2017)
Tesaro Inc. Revenue and Net Loss (2012-2016)
Tesaro Inc. R&D Expenditure (2012-2016)
Clovis Oncology Revenue and Net Loss (2012-2016)
Clovis Oncology R&D Expenditure (2014-2016)
AstraZeneca Revenue by Segments (2017)
Revenue and Net Profit (2013-2017)
Abbvie Inc. Revenue by Geographic (2017)
Abbvie Inc. Revenue and Net Earnings (2013-2017)
Abbvie Inc. R&D Expenditure (2014-2017)
LIST OF TABLES
Key PARP Inhibitors in Development
Current Trials of PARP/IO Combinations (2017)
Biomarkers Used in Ovarian Cancer (2017)
R&D Expenditure of Companies (2016/2017)
Key Players - Revenue & Market Cap Comparison (2016/2017)
PARP Inhibitor Development by Company (2017)
Tesaro Inc. Product Pipeline (2017)
Clovis Oncology Product Pipeline (2017)
AstraZeneca Oncology Product Pipeline (2017)
Abbvie Oncology Product Pipeline (2017)
Key PARP Inhibitors in Development
Current Trials of PARP/IO Combinations (2017)
Biomarkers Used in Ovarian Cancer (2017)
R&D Expenditure of Companies (2016/2017)
Key Players - Revenue & Market Cap Comparison (2016/2017)
PARP Inhibitor Development by Company (2017)
Tesaro Inc. Product Pipeline (2017)
Clovis Oncology Product Pipeline (2017)
AstraZeneca Oncology Product Pipeline (2017)
Abbvie Oncology Product Pipeline (2017)
